sitagliptin

GPTKB entity

Statements (51)
Predicate Object
gptkbp:instanceOf gptkb:drug
DPP-4 inhibitor
antidiabetic medication
gptkbp:approvalYear 2006
gptkbp:approvedBy gptkb:United_States
gptkbp:ATCCode A10BH01
gptkbp:brand gptkb:Januvia
gptkbp:CASNumber gptkb:486460-32-6
gptkbp:chemicalFormula C16H15F6N5O
gptkbp:combines gptkb:metformin
gptkb:phentermine
gptkb:ertugliflozin
gptkb:simvastatin
gptkbp:contraindication gptkb:diabetic_ketoacidosis
type 1 diabetes
gptkbp:developer gptkb:Merck_&_Co.
gptkbp:effect weight neutral
reduces blood glucose
lowers HbA1c
gptkbp:eliminationHalfLife 12.4 hours
gptkbp:excretion urine
https://www.w3.org/2000/01/rdf-schema#label sitagliptin
gptkbp:improves glycemic control
incretin levels
gptkbp:KEGGID D06402
gptkbp:legalStatus prescription only
gptkbp:mechanismOfAction inhibits DPP-4 enzyme
gptkbp:metabolism minimal
gptkbp:molecularWeight 407.31 g/mol
gptkbp:notRecommendedFor severe renal impairment
end-stage renal disease
gptkbp:patentExpired 2022 (US)
gptkbp:pregnancyCategory B (US)
gptkbp:prescribes adults
children (in some countries)
gptkbp:PubChem_CID gptkb:DB01261
gptkb:CHEMBL573
4369359
gptkbp:riskFactor pancreatitis
hypoglycemia (when combined with sulfonylureas)
gptkbp:routeOfAdministration oral
gptkbp:sideEffect gptkb:bullous_pemphigoid
headache
joint pain
allergic reactions
upper respiratory tract infection
nasopharyngitis
gptkbp:UNII X4W7ZR7023
gptkbp:usedFor gptkb:type_2_diabetes_mellitus
gptkbp:bfsParent gptkb:Januvia
gptkbp:bfsLayer 5